Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterologous Effects of BCG in Healthy Adults
NCT02380508Completed
- Sponsor
- University of Oxford
- Start
- Feb 2015
- Primary completion
- Nov 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of bcg vaccine in Tuberculosis (TB) (2 arms), sponsored by University of Oxford. Primary endpoint: Growth inhibition assays at Day 84. Started Feb 2015; status: completed.
02
Drugs
bcg vaccine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02380508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02380508.